PeptiCRAd-1 is a clinical oncolytic vaccine candidate comprised of VALO-D102 and two peptides containing clinically proven epitope sequences from NY-ESO-1 cancer-testis antigen28 and MAGE-A3 melanoma-associated antigen29 fused to polylysine linkers acting as positively charged moiety for electrostatic attachment of the peptides onto the viral capsid. This evidence concerns the gene MAGEA3 and melanoma.